Nuvo Pharmaceuticals Inc
F:23N
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Nuvo Pharmaceuticals Inc
F:23N
|
CA |
|
Kingfisher PLC
LSE:KGF
|
UK |
|
I
|
Ingredion Inc
F:CNP
|
US |
|
C
|
Caverion Oyj
OMXH:CAV1V
|
FI |
|
T
|
Tencent Music Entertainment Group
HKEX:1698
|
CN |
|
Metso Outotec Corp
OTC:OUKPY
|
FI |
|
Clicks Group Ltd
F:N1C
|
ZA |
|
A
|
Amdocs Ltd
F:AOS
|
US |
|
Banco de Sabadell SA
LSE:0H00
|
ES |
|
R
|
Red Robin Gourmet Burgers Inc
SWB:RRN
|
US |
|
Telefonaktiebolaget LM Ericsson
STO:ERIC A
|
SE |
|
B
|
Banco Santander SA
XBER:BSD2
|
ES |
|
Hiab Oyj
F:C1C1
|
FI |
|
C
|
China Oilfield Services Ltd
HKEX:2883
|
CN |
|
Shoprite Holdings Ltd
F:HY7A
|
ZA |
|
Eton Pharmaceuticals Inc
NASDAQ:ETON
|
US |
|
N
|
New Horizon Aircraft Ltd
NASDAQ:HOVR
|
CA |
|
C
|
Comstock Resources Inc
SWB:CX91
|
US |
|
C
|
California Water Service Group
XBER:WT5
|
US |
|
B
|
Barnes Group Inc
XBER:BG4
|
US |
|
L
|
Life Healthcare Group Holdings Ltd
JSE:LHC
|
ZA |
Nuvo Pharmaceuticals Inc
Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. The company is headquartered in Mississauga, Ontario and currently employs 100 full-time employees. The firm is engaged in offering diversified portfolio of commercial products. The company operates through three segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment is comprised of products commercialized by the Company in Canada. The company includes products, such as Blexten, Cambia, Suvexx and NeoVisc, as well as mature products. The Production and Service Business segment includes sale of products manufactured by the Company from its manufacturing facility in Varennes, Quebec or contracted by Miravo Ireland from its international headquarters in Dublin, Ireland, as well as service for testing, development and related quality assurance and quality control services provided by the Company. The Licensing and Royalty Business segment includes the revenue by the licensing of intellectual property and ongoing royalties from licensing agreements with partners.
Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. The company is headquartered in Mississauga, Ontario and currently employs 100 full-time employees. The firm is engaged in offering diversified portfolio of commercial products. The company operates through three segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment is comprised of products commercialized by the Company in Canada. The company includes products, such as Blexten, Cambia, Suvexx and NeoVisc, as well as mature products. The Production and Service Business segment includes sale of products manufactured by the Company from its manufacturing facility in Varennes, Quebec or contracted by Miravo Ireland from its international headquarters in Dublin, Ireland, as well as service for testing, development and related quality assurance and quality control services provided by the Company. The Licensing and Royalty Business segment includes the revenue by the licensing of intellectual property and ongoing royalties from licensing agreements with partners.
Revenue: Miravo posted adjusted total revenue of $18.2 million in Q3 2022, up from $17.1 million a year ago, driven by stronger commercial product sales.
Profitability: Adjusted EBITDA was $5.7 million, down from $7.0 million last year, as commercial gains were partly offset by lower licensing and manufacturing contribution plus higher operating expenses.
Growth brands: Blexten, Cambia and Suvexx all grew in the quarter, with Blexten and Suvexx delivering especially strong prescription growth and share gains.
Manufacturing exit: Management said Pennsaid 2% generic erosion has made the current manufacturing operation no longer viable, and Miravo is exploring strategic alternatives for the facility while winding down production.
Outlook: The company expects to keep supporting Pennsaid and Pennsaid 2% in some markets through third-party manufacturing and said the wind-down should conclude in the second half of 2023.
Business development: Management said new deal activity is a top priority, with several transactions in advanced discussions that could complement the current portfolio.
